berzosertib   Click here for help

GtoPdb Ligand ID: 8003

Synonyms: M6620 | VE 822 | VE-822 | VX-970 | VX970
Compound class: Synthetic organic
Comment: Berzosertib (VE-822) is a potent and selective inhibitor of the serine/threonine kinase ATR [7]. The structure of VE-822 is claimed in patent US20130089626 [6]. VE-822 is under investigated for its potential antineoplastic action [1,3].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 132.38
Molecular weight 463.17
XLogP 3.77
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CNCc1ccc(cc1)c1noc(c1)c1nc(cnc1N)c1ccc(cc1)S(=O)(=O)C(C)C
Isomeric SMILES CNCc1ccc(cc1)c1noc(c1)c1nc(cnc1N)c1ccc(cc1)S(=O)(=O)C(C)C
InChI InChI=1S/C24H25N5O3S/c1-15(2)33(30,31)19-10-8-18(9-11-19)21-14-27-24(25)23(28-21)22-12-20(29-32-22)17-6-4-16(5-7-17)13-26-3/h4-12,14-15,26H,13H2,1-3H3,(H2,25,27)
1. Charrier JD, Durrant SJ, Golec JM, Kay DP, Knegtel RM, MacCormick S, Mortimore M, O'Donnell ME, Pinder JL, Reaper PM et al.. (2011)
Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.
J Med Chem, 54 (7): 2320-30. [PMID:21413798]
2. Fokas E, Prevo R, Pollard JR, Reaper PM, Charlton PA, Cornelissen B, Vallis KA, Hammond EM, Olcina MM, Gillies McKenna W et al.. (2012)
Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.
Cell Death Dis, 3: e441. [PMID:23222511]
3. Gorecki L, Andrs M, Rezacova M, Korabecny J. (2020)
Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy.
Pharmacol Ther, 210: 107518. [PMID:32109490]
4. Konstantinopoulos PA, Cheng SC, Wahner Hendrickson AE, Penson RT, Schumer ST, Doyle LA, Lee EK, Kohn EC, Duska LR, Crispens MA et al.. (2020)
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol, 21 (7): 957-968. [PMID:32553118]
5. Minchom A, Aversa C, Lopez J. (2018)
Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies.
Ther Adv Med Oncol, 10: 1758835918786658. [PMID:30023007]
6. Pollard JR, Reaper PM. (2013)
Treating Cancer with ATR Inhibitors.
Patent number: US20130089626. Assignee: Vertex Pharmaceuticals Incorporated. Priority date: 30/09/2011. Publication date: 11/04/2013.
7. Shi Q, Shen LY, Dong B, Fu H, Kang XZ, Yang YB, Dai L, Yan WP, Xiong HC, Liang Z et al.. (2018)
The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
Cancer Lett, 432: 56-68. [PMID:29890208]